MISSION VIEJO, Calif.--(BUSINESS WIRE)--Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces the acquisition of a novel cyclosporine dry eye therapy patent portfolio from Newport Research. The acquisition includes an issued patent, an allowed patent and the rest of an intellectual property portfolio covering a broad formulation platform of a unique suspension comprising aqueous, amorphous nanodispersions of cyclosporine. Terms of the transaction were not disclosed.